UA42869C2 - Похідні саліцилової кислоти, спосіб одержання, фармацевтична композиція для лікування аутоімунного захворювання та спосіб лікування - Google Patents

Похідні саліцилової кислоти, спосіб одержання, фармацевтична композиція для лікування аутоімунного захворювання та спосіб лікування

Info

Publication number
UA42869C2
UA42869C2 UA94005499A UA94005499A UA42869C2 UA 42869 C2 UA42869 C2 UA 42869C2 UA 94005499 A UA94005499 A UA 94005499A UA 94005499 A UA94005499 A UA 94005499A UA 42869 C2 UA42869 C2 UA 42869C2
Authority
UA
Ukraine
Prior art keywords
salicylic acid
preparation
pharmaceutical composition
treatment method
acid derivatives
Prior art date
Application number
UA94005499A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Карл Хуберт Агбак
Лейф Ахргрен
Томас Берглінд
Томас Берглинд
Мартін Харальдссон
Мартин Харальдссон
Ларс-Інге Ольссон
Ларс-Инге ОЛЬССОН
Ййоран Смедегорд
Original Assignee
Кабі Фармаціа Аб
Каби Фармациа АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кабі Фармаціа Аб, Каби Фармациа АБ filed Critical Кабі Фармаціа Аб
Publication of UA42869C2 publication Critical patent/UA42869C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • C07D261/16Benzene-sulfonamido isoxazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UA94005499A 1991-11-18 1992-11-04 Похідні саліцилової кислоти, спосіб одержання, фармацевтична композиція для лікування аутоімунного захворювання та спосіб лікування UA42869C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
PCT/SE1992/000758 WO1993010094A1 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids

Publications (1)

Publication Number Publication Date
UA42869C2 true UA42869C2 (uk) 2001-11-15

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94005499A UA42869C2 (uk) 1991-11-18 1992-11-04 Похідні саліцилової кислоти, спосіб одержання, фармацевтична композиція для лікування аутоімунного захворювання та спосіб лікування

Country Status (29)

Country Link
US (3) US5302718A (enExample)
EP (1) EP0613468B1 (enExample)
JP (1) JP3259915B2 (enExample)
KR (1) KR100253748B1 (enExample)
AT (1) ATE194597T1 (enExample)
AU (1) AU668528B2 (enExample)
CA (1) CA2123697C (enExample)
DE (1) DE69231252T2 (enExample)
DK (1) DK0613468T3 (enExample)
EE (1) EE03026B1 (enExample)
ES (1) ES2149780T3 (enExample)
FI (1) FI106857B (enExample)
GR (1) GR3034585T3 (enExample)
HU (2) HU221476B (enExample)
IL (1) IL103665A (enExample)
LT (1) LT3182B (enExample)
LV (1) LV10246B (enExample)
MX (1) MX9206647A (enExample)
MY (1) MY130169A (enExample)
NO (1) NO300805B1 (enExample)
NZ (1) NZ244998A (enExample)
PT (1) PT101068B (enExample)
RU (1) RU2124501C1 (enExample)
SE (1) SE9103397D0 (enExample)
SK (1) SK282080B6 (enExample)
TW (1) TW304944B (enExample)
UA (1) UA42869C2 (enExample)
WO (1) WO1993010094A1 (enExample)
ZA (1) ZA928864B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6028052A (en) 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CN1211183A (zh) 1996-02-20 1999-03-17 布里斯托尔-迈尔斯斯奎布公司 联苯基异噁唑磺酰胺的制备方法
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 4−フルオロサリチル酸類
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
CA2334545A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
HK1039778A1 (zh) 1999-03-19 2002-05-10 Bristol-Myers Squibb Company 制造联苯异恶唑基磺胺的方法
DE60031699T2 (de) 1999-09-04 2007-08-30 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
CN1235877C (zh) 1999-09-04 2006-01-11 阿斯特拉曾尼卡有限公司 升高丙酮酸脱氢酶活性的取代的n-苯基2-羟基-2-甲基-3,3,3-三氟代丙酰胺衍生物
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
AU2001254559A1 (en) * 2000-04-28 2001-11-12 The University Of British Columbia Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100360342B1 (ko) * 2002-04-19 2002-11-13 박계정 밸런스 머신의 언밸런스 수정위치 및 수정량의 자동 보상방법
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
KR20060101772A (ko) * 2003-12-19 2006-09-26 화이자 인코포레이티드 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-hsd-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물
WO2006003517A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
RU2481329C2 (ru) * 2008-06-23 2013-05-10 Астеллас Фарма Инк. Сульфонамидные соединения или их соли
AU2012220620A1 (en) * 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
JPH07501330A (ja) 1995-02-09
DK0613468T3 (da) 2000-10-23
TW304944B (enExample) 1997-05-11
AU2958992A (en) 1993-06-15
WO1993010094A1 (en) 1993-05-27
ATE194597T1 (de) 2000-07-15
NZ244998A (en) 1995-09-26
KR100253748B1 (ko) 2000-05-01
EP0613468A1 (en) 1994-09-07
IL103665A0 (en) 1993-04-04
FI942289L (fi) 1994-05-17
GR3034585T3 (en) 2001-01-31
AU668528B2 (en) 1996-05-09
PT101068B (pt) 1999-08-31
HU221476B (en) 2002-10-28
HU211163A9 (en) 1995-10-30
PT101068A (pt) 1994-02-28
EE03026B1 (et) 1997-08-15
CA2123697A1 (en) 1993-05-27
CA2123697C (en) 2003-12-09
IL103665A (en) 1997-08-14
NO941799L (enExample) 1994-06-22
LT3182B (en) 1995-03-27
ES2149780T3 (es) 2000-11-16
MX9206647A (es) 1993-05-01
ZA928864B (en) 1993-05-13
US5403930A (en) 1995-04-04
US5556855A (en) 1996-09-17
SK282080B6 (sk) 2001-10-08
JP3259915B2 (ja) 2002-02-25
SK54794A3 (en) 1995-02-08
SE9103397D0 (sv) 1991-11-18
LV10246A (lv) 1994-10-20
RU2124501C1 (ru) 1999-01-10
US5302718A (en) 1994-04-12
FI942289A0 (fi) 1994-05-17
FI106857B (fi) 2001-04-30
LTIP229A (en) 1994-09-25
MY130169A (en) 2007-06-29
NO300805B1 (no) 1997-07-28
DE69231252D1 (de) 2000-08-17
NO941799D0 (no) 1994-05-13
DE69231252T2 (de) 2001-03-01
HU9401391D0 (en) 1994-08-29
LV10246B (en) 1995-04-20
HUT69723A (en) 1995-09-28
EP0613468B1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
UA42869C2 (uk) Похідні саліцилової кислоти, спосіб одержання, фармацевтична композиція для лікування аутоімунного захворювання та спосіб лікування
ATE40819T1 (de) 4-vinylbenzoesaeure-derivate, ihre herstellung und verwendung als arzneimittel und ligande.
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
PT100606A (pt) Derivados fluoroalcoxibenzilamino de heterociclos contendo azoto
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
KR950702181A (ko) 20-위치가 변형된 비타민 D계열의 유도체, 이들의 제조 방법, 이 제조 방법을 위한 중간 생성물, 이들 유도체를 함유하는 제약 제제, 및 약제 제조를 위한 이들의 용도(Derivatives in the Vitamin D Series Modified at the 20 Position a Method of Preparing Such Derivatives, Intermediates Used in This Method, Pharmaceutical Preparations Containing the Derivatives and Their Use in the Preparation of Drugs)
ATE138650T1 (de) Substituierte 4-phenyl-4-piperidincarboxamide mit sowohl lokalanästhetischer als auch schmerzlindernder wirkung sowie verfahren zur herstellung
ES8700664A1 (es) Un metodo para producir derivados de 1,5 benzoxazepina.
DK0883619T3 (da) Morfin- og diamorfinsalte af anioniske ikke-narkotiske analgetika af substitueret carboxylsyretype
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
DE69226487D1 (de) Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
ATE62908T1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
ATE21101T1 (de) N-iminopyridinium-betain-derivate, ihre herstellung und ihre verwendung als arzneimittel.
FI954138A0 (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
NO873564L (no) Nye tyroninderivater.
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
ATE139441T1 (de) Verwendung von 2-iminothiazolidin-4-onderivaten als neuartige arzneimittelwirkstoffe
NO982107L (no) Fremstilling av et salt av klavulansyre
ZA961044B (en) New pyridine and pyridazine derivatives, processes for the production thereof and pharmaceutical agents containing these compounds.
PT99280A (pt) Processo de preparacao de derivados do indolo e de composicoes farmaceuticas
FI925618A0 (fi) Etanoladdukter av 6-sulfonylsubstituerade 3-hydroxikromaner och deras anvaendning som inhalationsmedel vid sjukdomar
PT84077A (de) Neue thyroninderivate
ATE121724T1 (de) Neue salze der 2-(2,6-dichloranilino)- phenylessigsäure, verfahren zu ihrer herstellung und ihre verwendung für topisch anwendbare pharmazeutische zubereitungen.
FR2367075A1 (fr) Nouvelles tropinones substituees en position 6 et procede pour leur preparation
ATE221068T1 (de) Anellierte beta-carboline